Xenon Pharmaceuticals (XENE) Cash from Financing Activities (2013 - 2026)

Xenon Pharmaceuticals (XENE) has 14 years of Cash from Financing Activities data on file, last reported at $843.0 million in Q1 2026.

• Cash from Financing Activities for Q1 2026 came in at $843.0 million, up 73141.79% year-over-year; the trailing twelve-month figure through Mar 2026 was $959.0 million (up 7120.65% YoY), and the FY2025 annual result was $117.1 million, up 865.48% from the prior year.
• Cash from Financing Activities advanced to $843.0 million in Q1 2026 per XENE's latest filing, from $113.5 million in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $843.0 million in Q1 2026 and troughed at $6000.0 in Q4 2022.
• A 5-year average of $143.2 million and a median of $7.9 million in 2022 frame the typical range for Cash from Financing Activities.
• The sharpest annual moves came in 2022 and 2023: Cash from Financing Activities plunged 100.0% in 2022, then jumped 5400133.33% in 2023.
• A 5-year view of Cash from Financing Activities shows it stood at $6000.0 in 2022, then jumped by 5400133.33% to $324.0 million in 2023, then slumped by 96.26% to $12.1 million in 2024, then surged by 836.0% to $113.5 million in 2025, then jumped by 642.5% to $843.0 million in 2026.
• Business Quant data shows XENE's Cash from Financing Activities at $843.0 million in Q1 2026, $113.5 million in Q4 2025, and $2.4 million in Q3 2025.